Table 2 Multivariate Cox's overall survival and malignant progression-free survival analysis.

From: Subventricular zone involvement is associated with worse outcome in glioma WHO grade 2 depending on molecular markers

Covariate

Overall survival

Malignant progression-free survival

Hazard ratio

95% confidence interval

p value

Hazard ratio

95% confidence interval

p value

Subventricular zone involvement

3.73

1.1–12.7

0.036*

2.81

1.4–5.5

0.003*

Molecular markers

IDH mutation

0.92

0.0–0.5

0.006*

0.33

0.1–1.0

0.049*

MGMT methylation

0.22

0.0–1.4

0.111

0.38

0.1–1.1

0.082

1p19q codeletion

0.47

0.1–1.6

0.236

0.52

0.3–1.0

0.061

Demographics

Age

1.01

1.0–1.1

0.784

0.99

1.0–1.0

0.430

Male sex

2.35

0.8–7.0

0.125

1.52

0.8–2.9

0.212

Therapy

Surgical resection

0.89

0.2–4.8

0.896

0.94

0.3–2.9

0.915

Medical therapy

1.82

0.3–11.1

0.518

1.00

0.3–3.2

1.000

Wait-and-scan

1.33

0.2–11.5

0.798

1.17

0.3–4.6

0.819

  1. Multivariate overall survival and malignant progression-free survival analysis was performed among WHO grade 2 glioma patients (n = 182) using clinical and molecular covariates. Molecular markers, sex, and therapeutic approaches were tested as dichotomous variables, and age was tested as continuous variable. Hazard ratio, 95% confidence interval, and p value are given for analyzed covariates. Asterisks indicate p ≤ 0.05.
  2. IDH isocitrate dehydrogenase 1/2, MGMT O6-methylguanine-DNA methyltransferase promotor.
Back to article page